Sean Wharton

26PUBLICATIONS
69CO-AUTHORS
Nutrigenomics and personalised nutritionExercise physiologyIsotope geochemistryPharmacogenomicsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Oct 01, 2026
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

|Sep 20, 2026
Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.

|Jun 24, 2026
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.

|Jun 13, 2026
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.

|Apr 23, 2026
Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.

|Nov 11, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Sean Wharton, Carel W le Roux, Biykem Bozkurt

Pageof 5

Frequent Collaborators

4 joint publications

Rebecca Ag Christensen

4 joint publications

Carel W le Roux

4 joint publications

Ildiko Lingvay

4 joint publications

Domenica Rubino